Milestone Pharmaceuticals, Inc.

Developing fast-acting intranasal drugs to resolve cardiac rhythm disorders

Milestone Pharmaceutical develops novel small molecule therapeutics for transient cardiovascular conditions. The company’s lead product, etripamil (MSP-2017) is a potent, short-acting nasally-delivered calcium channel antagonist in phase 3 development for the episodic treatment of paroxysmal supraventricular tachycardia (PSVT).

  • CEO Joseph Oliveto, MBA
  • Industry Biotech